Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
Major drug wholesaler Alfresa Holdings has formed a business alliance with K Pharma to build a supply chain for KP8011, an iPS cell-derived regenerative medicine product being developed by the Keio University-originated biotech for subacute spinal cord injury. Under the…
To read the full story
Related Article
BUSINESS
- Leqembi Subcutaneous Autoinjector Gets Priority Review in China
February 10, 2026
- Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai
February 9, 2026
- Marubeni Rolls Out Antibiotic Xenleta in China
February 9, 2026
- HLC, Mochida Set to Launch Japan PIII Trial of Umbilical Cord-Derived MSC
February 9, 2026
- Japan Ethical Drug Sales Up 3.2% in December: Crecon
February 9, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…